Plasmin-binding Vhhs

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel single-domain antibodies (VHHs or nanobodies) that specifically bind to the human enzyme plasmin. These VHHs enhance the activity of plasmin, leading to accelerated breakdown of fibrin clots (fibrinolysis and thrombolysis). The invention includes pharmaceutical compositions containing these VHHs, potentially as stand-alone agents or combined with other components, for treating or preventing conditions characterized by abnormal blood clotting, such as embolism, stroke, or thrombosis. The VHHs can be formulated for various routes of administration or incorporated into medical devices.

Use CasesContent extracted from patent full text and abstract with AI.

• Emergency treatment of acute thrombotic or embolic events such as stroke, pulmonary embolism, or myocardial infarction.
• Adjunct therapy to enhance clot breakdown in patients at risk of or suffering from deep vein thrombosis or venous occlusive disease.
• Prevention or reduction of clot formation in medical devices like stents or catheters by coating or integrating the VHHs.
• Therapeutic use in microthrombotic disorders, acute ischemic stroke, or conditions with impaired endogenous fibrinolysis.
• Combination therapy with established thrombolytic drugs to reduce their required dosage or enhance efficacy.

BenefitsContent extracted from patent full text and abstract with AI.

• Faster and more effective dissolution of blood clots compared to traditional therapies.
• High specificity for plasmin reduces undesired effects on other proteins or pathways, potentially improving safety.
• Small size of VHHs allows better tissue penetration and may enable routes of administration (e.g., intravenous, subcutaneous) that are less feasible for conventional antibodies.
• Potential to reduce the risk of bleeding complications by preserving other components of the coagulation system (e.g., protecting factor V from degradation).
• Adaptability for use in both acute emergency settings and for chronic prophylactic applications.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The disclosure relates to a VHH specifically binding to plasmin. The disclosure further relates to a compound or a pharmaceutical composition comprising the VHH and to the use thereof in the treatment, prevention or amelioration of a disease or condition characterized by a thrombotic or embolic state.